Related Experiment Video
Updated: Jun 25, 2026

Ginger Moxibustion, A Non-pharmacological Treatment, for Diarrhea in Patients with Chronic Obstructive Pulmonary Disease
Published on: December 27, 2024
[Progress in 2008 for acid related diseases]
P Jornod1, D Vouillamoz, F Viani
1Service de gastroentérologie et d'hépatologie, CHUV, 1011 Lausanne.
Abstract:
The treatment of reflux disease did not change in the review period. PPI therapy remains the first line treatment and surgery the second line approach. Endoscopic anti-reflux procedures should be only performed in controlled studies. Beside the classic triple therapy, sequential treatment of Helicobacter pylori infection can today be considered as a first line therapy. PPI are effective in the prevention of gastroduodenal lesions and in the treatment of dyspeptic symptoms induced by NSAIDs treatment. Only patients younger then 65 years and without any risk factors do not need a preventive PPI prescription during classic NSAIDS treatment.
Insights
Proton pump inhibitors (PPIs) remain the primary treatment for reflux disease and NSAID-induced symptoms. Sequential therapy is now a first-line option for H. pylori infections.
Area of Science:
- Gastroenterology
- Pharmacology
Context:
- Review of current treatment guidelines for gastroesophageal reflux disease (GERD) and Helicobacter pylori (H. pylori) infection.
- Evaluation of the role of proton pump inhibitors (PPIs) in managing NSAID-induced gastroduodenal lesions and dyspeptic symptoms.
Purpose:
- To summarize the current evidence-based treatment strategies for reflux disease and H. pylori infection.
- To clarify the appropriate use of PPIs in patients undergoing NSAID treatment.
Summary:
- Proton pump inhibitors (PPIs) are the first-line treatment for reflux disease, with surgery as a second-line option. Endoscopic anti-reflux procedures require further controlled studies.
- Sequential treatment is now a recognized first-line therapy for H. pylori infection, alongside classic triple therapy.
- PPIs effectively prevent gastroduodenal lesions and treat NSAID-induced dyspepsia. Preventive PPIs are recommended for patients over 65 or those with risk factors during NSAID therapy.
Impact:
- Provides clinicians with updated, evidence-based recommendations for managing common gastrointestinal conditions.
- Optimizes the use of PPIs, potentially reducing unnecessary prescriptions and healthcare costs.
- Highlights the evolving landscape of H. pylori treatment strategies.
Related Concept Videos
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Peptic Ulcer Disease I: Introduction
